AI is now baked into the day-to-day work of pharma and healthtech companies. It is helping teams forecast demand, flag adverse events earlier, speed up patient support, and personalise care journeys. But in B2B, adoption is rarely blocked by the model. It is blocked by trust. Buyers want to know one thing before they sign: will this be safe, compliant, and defensible when something goes wrong?

This matters even more in India because digital health is scaling quickly. Under the Ayushman Bharat Digital Mission, the Government has reported 79.91 crore ABHA accounts created and 67.19 crore health records linked as of 5 August 2025. When an ecosystem is this large, expectations around privacy, security, and responsible data use rise automatically.

Compliance is no longer a checkbox

Until recently, many companies treated compliance as something handled by legal teams after the product was built. That approach does not work with AI, especially in healthcare. The data is sensitive, the outcomes affect real people, and audits can be unforgiving.

India’s privacy framework is also becoming clearer. The Digital Personal Data Protection (DPDP) Act, 2023 as per the Ministry of Electronics and Information Technology, sets the base rules for lawful processing of digital personal data. In 2025, the Government notified the DPDP Rules, 2025, which it described as operationalising the Act into a more complete, citizen-centric framework. For B2B buyers, this translates into stronger questions during procurement: consent, purpose limitation, retention, breach handling, and vendor accountability.

What “secure AI” looks like in practice

For pharma and healthtech companies selling to enterprises, compliance has to be product-shaped. That means the platform must help customers follow the rules without creating more work for them.

A strong starting point is data discipline. Use only what is necessary for a defined purpose, keep it for only as long as required, and make it easy to delete when the relationship ends. In enterprise sales, this is not just a privacy principle. It is a practical sales advantage because security teams immediately look for over-collection and unclear retention.

Next is access control. A lot of real-world risk is not hackers. It is internal misuse, shared credentials, overbroad admin access, and vendor sprawl. Buyers want role-based access, audit logs, and clear visibility into who touched what data and when.

Then comes model governance. In healthcare, you need clarity on whether the AI is assisting, recommending, or making a decision. Enterprises prefer tools that keep a human in the loop, especially for clinical decisions, patient communication, and compliance-sensitive workflows. This is also where explainability matters. Not academic explainability, but operational explainability. If a compliance officer asks why a patient was flagged as high risk, the system should give a sensible trace, not a black box.

B2B growth depends on procurement readiness

Sustainable growth in pharma and healthtech is driven by repeatable enterprise wins. That requires being ready for procurement from day one. In practice, this means having a clean security posture: documented policies, periodic testing, incident response plans, and clear contracts that define responsibilities between the buyer and the vendor.

It also means being integration-ready. Many buyers will insist on fitting AI tools into their existing stack. If your product cannot integrate with identity providers, logging systems, or data governance tools, your sales cycle will drag, even if the product is good.

Finally, customers increasingly want proof that the system is safe at scale. With ABDM expanding registries, facilities, and record linkages, organisations are more sensitive to how health data is stored, shared, and processed across partners. A vendor that can demonstrate strong safeguards, clean documentation, and disciplined data handling will be easier to approve.

Also read: Reimagining Healthcare Financing in India’s Out-of-Pocket Economy

The simple reality for 2026

AI will keep getting cheaper and faster. Trust will not. In pharma and healthtech, the companies that grow sustainably will be the ones that treat security and compliance as part of the product, not as paperwork that comes later. Buyers are not looking for perfection. They are looking for clarity, control, and accountability. If you can offer that, you do not just win deals. You keep them.

Views expressed by: Ranga Rao V., Chief AI Architect, [x]cube LABS 

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or views of any organisation. The content is intended for informational and educational purposes only and should not be construed as medical advice.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!